Point72 Asia (Singapore)’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Point72 Asia (Singapore)’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-48,720	Closed	-$6.43M	–	1333
2025 Q1	$6.43M	Buy	+48,720	New	+$6.07M	1.69%	10

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Point72 Asia (Singapore)'s ITCI Position: Q2 2025 in Review

Point72 Asia (Singapore) sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 48,720 shares — an estimated $6.43M sold.

Point72 Asia (Singapore) first reported a position in ITCI in Q1 2025 and held it in 1 quarter. The position peaked at $6.43M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Point72 Asia (Singapore) reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Point72 Asia (Singapore) sold 48,720 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $6.43M.
Point72 Asia (Singapore) first reported a position in Intra-Cellular Therapies Inc. in Q1 2025 and held it in 1 quarter.
Point72 Asia (Singapore)'s Intra-Cellular Therapies Inc. position peaked at $6.43M in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q2 2025, filed 14 Aug 2025.